Improved survival for patients with chronic blood diseases

July 17, 2012

(Medical Xpress) -- New research from Karolinska Institutet shows that the survival for patients with chronic myeloproliferative diseases has improved in recent decades. This is despite the fact that no targeted drugs have yet been registered for this group of diseases. More than 9,000 patients have been included in a unique population-based study which has been published in the Journal of Clinical Oncology.

In Sweden, around 450 people are diagnosed each year with chronic myeloproliferative diseases, a group of three disease subtypes that are characterized by the production of excess cells in the bone marrow. Polycythemia vera results in the overproduction of , essential thrombocytosis leads to the overproduction of , and primary involves the overproduction of connective tissue in the bone marrow, leading to decreasing blood counts.

These diseases also involve an increased risk of complications such as (thrombosis) and bleeding (hemorrhage). The treatment, provided in the form of phlebotomy, radioactive phosphorus, or cytotoxic agents, aims primarily to alleviate symptoms and reduce the risk of complications.

The study included all cases of chronic myeloproliferative diseases reported to the Swedish Cancer Registry between 1973 and 2008, a total of 9,384 patients. The results show that even patients with the mildest form of myeloproliferative disease - essential thrombocytosis - have a lower life expenctancycompared with the normal population, which has not previously been thought to be the case.

In contrast to certain previously published studies, patients suffering from polycythemia vera were also shown to have a shorter life expectancy. As expected, primary myelofibrosis patients had a shorter life expectancy compared with the normal population.

"At the same time, we note that the for patients with polycythemia vera and essential thrombocytosis have improved during the study period. This is very encouragingm", says Malin Hultcrantz, who led the study.

For essential thrombocytosis patients, the life expectancy was almost at the same level as the normal population during the most recent period, 2001 to 2008.

"There is a great deal of interest within medical research in devising and developing new treatments for these diseases", says Malin Hultcrantz. "We hope that the prognosis in myeloproliferative diseases will continue to improve, ideally at a faster rate."

Explore further: Cell signaling discovery provides new hope for blood disorders

More information: Malin Hultcrantz, Sigurdur Yngvi Kristinsson, Therese M-L Andersson, Ola Landgren, Sandra Eloranta, Åsa Rangert Derolf, Paul W. Dickman & Magnus Björkholm, Patterns of survival among 9,384 patients with myeloproliferative neoplasms diagnosed in Sweden 1973-2008; a population-based study, jco.ascopubs.org/

Related Stories

Cell signaling discovery provides new hope for blood disorders

February 16, 2012
Walter and Eliza Hall Institute scientists have revealed new details about how cell signalling is controlled in the immune system, identifying in the process potential new therapeutic targets for treating severe blood disorders.

No higher risk of acute leukaemia in close relatives

December 15, 2011
(Medical Xpress) -- Parents, siblings and children of patients with the most common form of acute leukemia do not run a higher risk of developing the disease as was once believed, according to a new study from the Swedish ...

The Medical Minute: What is myelodysplastic syndrome?

June 15, 2012
Television journalist and host of "Good Morning America" Robin Roberts announced this week that she has myelodysplastic syndrome, or MDS, an uncommon blood and bone marrow disorder.

'PARP' drug sabotages DNA repair in pre-leukemic cells

December 12, 2011
Looking for ways to halt the uncontrolled growth of cancer cells, scientists at Johns Hopkins have found that a new class of drugs, called PARP inhibitors, may block the ability of pre-leukemic cells to repair broken bits ...

Recommended for you

Encouraging oxygen's assault on iron may offer new way to kill lung cancer cells

November 22, 2017
Blocking the action of a key protein frees oxygen to damage iron-dependent proteins in lung and breast cancer cells, slowing their growth and making them easier to kill. This is the implication of a study led by researchers ...

One-size treatment for blood cancer probably doesn't fit all, researchers say

November 22, 2017
Though African-American men are three times more likely to be diagnosed with a blood cancer called multiple myeloma, most scientific research on the disease has been based on people of European descent, according to a study ...

One in four U.S. seniors with cancer has had it before

November 22, 2017
(HealthDay)—For a quarter of American seniors, a cancer diagnosis signals the return of an old foe, new research shows.

Combination immunotherapy targets cancer resistance

November 22, 2017
Cancer immunotherapy drugs have had notable but limited success because in many cases, tumors develop resistance to treatment. But researchers at Yale and Stanford have identified an experimental antibody that overcomes this ...

Researchers discover specific tumor environment that triggers cells to metastasize

November 21, 2017
A team of bioengineers and bioinformaticians at the University of California San Diego have discovered how the environment surrounding a tumor can trigger metastatic behavior in cancer cells. Specifically, when tumor cells ...

New study points the way to therapy for rare cancer that targets the young

November 21, 2017
After years of rigorous research, a team of scientists has identified the genetic engine that drives a rare form of liver cancer. The findings offer prime targets for drugs to treat the usually lethal disease, fibrolamellar ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.